A therapy by CLS

imILTCLS (immunostimulating Interstitial Laser Thermotherapy by CLS) is a new, promising treatment in the growing field of cancer immunotherapy. The minimally invasive, thermal treatment is performed using the TRANBERGCLS | Cancer Immunotherapy System designed to achieve local tumor destruction and specific anti-tumor immunity.


  • Local tumor destruction

    The principle is simple but the treatment requires precision. By achieving low, not coagulating temperatures in the area of the tumor border, intact tumor antigens are released. This creates a specific immune response against remaining tumor, including disease at other sites.

    The laser-generated heat induces destruction of the targeted tumor. The treatment process is controlled by tissue temperature feedback, which gives close control of temperature levels at the tumor border and lesion size.

    Read more
  • Systemic immune activation

    During and after imILT intact, non-coagulated tumor antigens are released and exposed to the immune system. At the same time the treatment creates a beneficial tumor immune microenvironment. Antigen presenting cells (APCs), such as dendritic cells (DCs) and macrophages, present the tumor antigens to T cells, mainly cytotoxic T cells. The result is systemic immune activation against remaining tumor.

    Read more
  • Mobile laser unit

    Our new TRANBERGCLS | Cancer Immunotherapy System include a laptop design mobile diode laser unit and disposable accessories specifically designed for safe and efficient performance of the imILTCLS cancer immunotherapy procedure.

    Read more
  • Combined Therapies

    Treatment with imILTCLS has no dose limitation and can be repeated as required. imILTCLS can be combined with surgery, radiation therapy, vascular occlusion therapies and cytostatic, angiostatic and immunomodulating drugs.

    Read more
  • Based on 20 years of research

    The design of the new TRANBERGCLS|Cancer Immunotherapy System and the imILTCLS protocol is based on research, performed by Professor K-G Tranberg and his team at Lund University in Sweden, during the two last decades.

    Our history Visit CLS